RESEARCH ARTICLE

Population-Based Incidence Rates of Diarrheal Disease Associated with Norovirus, Sapovirus, and Astrovirus in Kenya

Kayoko Shioda1,2*, Leonard Cosmas3, Allan Audi4, Nicole Gregoricus1, Jan Vinjé1, Umesh D. Parashar1, Joel M. Montgomery3, Daniel R. Feikin3aa, Robert F. Breiman3ab, Aron J. Hall1

1 Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2 Oak Ridge Institute for Science and Technology, Oak Ridge, Tennessee, United States of America, 3 Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya, 4 Kenya Medical Research Institute, Center for Global Health Research, Nairobi, Kenya

¤ Current address: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Background

Diarrheal diseases remain a major cause of mortality in Africa and worldwide. While the burden of rotavirus is well described, population-based rates of disease caused by norovirus, sapovirus, and astrovirus are lacking, particularly in developing countries.

Methods

Data on diarrhea cases were collected through a population-based surveillance platform including healthcare encounters and household visits in Kenya. We analyzed data from June 2007 to October 2008 in Lwak, a rural site in western Kenya, and from October 2006 to February 2009 in Kibera, an urban slum. Stool specimens from diarrhea cases of all ages who visited study clinics were tested for norovirus, sapovirus, and astrovirus by RT-PCR.

Results

Of 334 stool specimens from Lwak and 524 from Kibera, 85 (25%) and 159 (30%) were positive for norovirus, 13 (4%) and 31 (6%) for sapovirus, and 28 (8%) and 18 (3%) for astrovirus, respectively. Among norovirus-positive specimens, genogroup II predominated in both sites, detected in 74 (87%) in Lwak and 140 (88%) in Kibera. The adjusted community incidence per 100,000 person-years was the highest for norovirus (Lwak: 9,635; Kibera: 4,116), followed by astrovirus (Lwak: 3,051; Kibera: 440) and sapovirus (Lwak: 1,445; Kibera: 879). For all viruses, the adjusted incidence was higher among children aged <5 years (norovirus: 22,225 in Lwak and 17,511 in Kibera; sapovirus: 5,556 in Lwak and 4,378 in Kibera).
in Kibera; astrovirus: 11,113 in Lwak and 2,814 in Kibera) compared to cases aged ≥5 years.

**Conclusion**

Although limited by a lack of controls, this is the first study to estimate the outpatient and community incidence rates of norovirus, sapovirus, and astrovirus across the age spectrum in Kenya, suggesting a substantial disease burden imposed by these viruses. By applying adjusted rates, we estimate approximately 2.8–3.3 million, 0.45–0.54 million, and 0.77–0.95 million people become ill with norovirus, sapovirus, and astrovirus, respectively, every year in Kenya.

**Introduction**

Although global deaths from diarrheal disease have decreased from 2.6 million to 1.3 million between 1990 and 2013 [1], it remains a major health concern, particularly in Africa. Diarrheal illness was estimated to be one of the top causes of years of life lost in sub-Saharan Africa in 2013, along with HIV/AIDS, lower respiratory infections, and malaria [1]. Young children are known to be the most affected population, and there were an estimated 450 million diarrheal episodes among children <5 years of age in 2010 in Africa [2]. The burden of rotavirus, which remains the leading cause of severe diarrheal disease in children worldwide, has been well characterized in both developed and developing countries [3–8]. Although norovirus, sapovirus, and astrovirus are also recognized as contributors to diarrheal disease [9], population-based rates of disease associated with these viruses are not available in sub-Saharan African countries. With the expected decline of rotavirus disease after vaccine implementation [10–13], monitoring for other diarrheal pathogens will be important to assess changes in their relative burden in order to implement appropriate public health measures, especially in regions with high incidence of diarrheal diseases.

To help fill this gap, we aimed to estimate population-based rates of diarrheal illness associated with norovirus, sapovirus, and astrovirus in Kenya. We used a unique active surveillance system for infectious disease syndromes implemented by the Kenya Medical Research Institute (KEMRI) and the United States Centers for Disease Control and Prevention (CDC) to achieve this goal.

**Materials and Methods**

**Population-based infectious disease surveillance**

The population-based infectious disease surveillance (PBIDS) system was launched in late 2005 by CDC and KEMRI. The system encompassed two sites in Kenya: Lwak and Kibera (Fig 1). Lwak is a rural location in Nyanza province (current Kisumu Country) near Lake Victoria in Western Kenya, which is one of the poorest areas in the country. Kibera is an urban slum in Nairobi, which is the capital and the largest city in Kenya. The geographic characteristics of these surveillance areas have been described previously [14, 15]. The study periods for this analysis was from June 2007 to October 2008 (one year and five months) in Lwak and from October 2006 to February 2009 (two years and five months) in Kibera.

The PBIDS system has been described in detail [15]. Briefly, it targets infectious disease syndromes, such as diarrheal disease, febrile illness, pneumonia, and jaundice. All residents of all
ages in both surveillance sites were eligible for enrollment, as long as they had lived in the region for more than four consecutive months during the study period. Neonates born to a mother enrolled in PBIDS were also offered enrollment.

One unique aspect of the PBIDS system is that it includes both household surveillance and clinic surveillance. In the household surveillance, trained community interviewers visited all enrolled household every two weeks and asked participants about illnesses and deaths that
occurred since the last visit using standardized questionnaires. If a participant was absent or unable to answer the questions, a proxy who had the information of the participant’s health was interviewed. Mothers or other primary caretakers were interviewed if children were not able to answer the questions. Community interviewers also conducted focused physical exams on sick participants during the visit. The exam consisted of measuring axillary temperature and respiratory rate, evaluating for signs of respiratory distress in ill children, and observing signs of dehydration. For the clinic surveillance, a centrally located health care facility was identified in each study site, which was located within 5 km or 1 km of all people living in Lwak and Kibera, respectively. All surveillance participants received free medical care at these study clinics for all acute infectious conditions. Detailed information was collected for all sick visits using structured questionnaires and specimens were collected from patients meeting case definitions (see below).

Specimen collection and diagnostics

At the study clinics, stool specimens were collected from consenting patients of all ages who met at least one of three criteria. The first criterion was uncomplicated diarrhea, which was defined as three or more loose stools within a 24-hour period, without signs or symptoms of dehydration or dysentery. Because there were many patients meeting this criterion, a maximum of six stool specimens were collected from patients with uncomplicated diarrhea per day in each study site: three from patients ≥5 years of age and three from patients <5 years of age. The second criterion was having complicated diarrhea based on the presence of signs and symptoms of dehydration, which was defined as drinking eagerly, being unable to drink or breastfeed, emesis, slow capillary refill (two seconds or more), irritability, sunken eyes, lethargy or unconsciousness. In this group, stool specimens were attempted to be collected from all consenting patients. The third criterion was having dysentery, which was defined as reported or visible blood in one or more stool within 24 hours of clinic visit. We aimed to collect stool specimens from all patients meeting this criterion. If participants were unable to produce stool at the clinic, patients were sent home with stool cups and instructions, and stool specimens were collected from their homes within four hours of clinic visits.

The stool specimens were aliquoted at KEMRI-CDC laboratories in Kenya and stored at −80°C and then an aliquot from each patient was batch shipped to the CDC laboratory in Atlanta, Georgia, on dry ice to test for norovirus, sapovirus, and astrovirus. Viral nucleic acid was extracted from stool suspensions according to the MagMAX-96 Viral RNA Isolation KIT protocol (Ambion, Austin, Texas) on the KingFisher instrument (Thermo Scientific, Vantaa, Finland). Viral nucleic acid was then tested for norovirus genogroup I and II, sapovirus, and astrovirus using TaqMan real-time reverse-transcription polymerase chain reaction (RT-qPCR) [16–20].

In addition to these three enteric viruses, stool specimens were tested for rotavirus using a commercially available enzyme immunoassay kit (Rotaclone, Meridian Premier, Charlotte, North Carolina), as previously described [21], and were cultured for Salmonella, Shigella, Campylobacter, and Vibrio species by standard techniques [22].

Analysis of incidence

Data were analyzed using SAS, version 9.3 (SAS Institute, Cary, North Carolina). Crude incidence was calculated as the number of diarrheal illness episodes with stool specimens testing positive for norovirus, sapovirus, or astrovirus among PBIDS participants per 100,000 participant person-years of observation (PYO). If a patient experienced multiple episodes of diarrhea more than 14 days apart from each other, we considered them as unique episodes and counted
them separately in the numerator. PYO was calculated by dividing the sum of person-days for all participants who met the surveillance inclusion criteria by $365.25$. A participant who moved away from the surveillance area for longer than four consecutive months was not counted in the denominator for calculation of PYO during or after the leave. If that person returned to the surveillance area, he/she was not counted in denominator or numerator until confirmed to be living in the surveillance area for at least four consecutive months and re-consented to participate in the study.

To assess the seasonality of norovirus, sapovirus, and astrovirus-associated diarrheal illnesses, we calculated annualized crude incidence rates in each month as follows:

$$ Annualized \text{ crude incidence per 100,000 PYO in each month} = \frac{\text{Average number of positive specimens in each month}}{\text{PYO}} \times 12 \times 100,000 $$

In order to estimate incidence of the viral diarrhea cases at the outpatient and community levels, we applied three adjustment factors to the crude incidence rates to account for the potentially undetected cases at the study clinics. The first adjustment factor was the proportion of patients whose stool specimens were submitted and tested among all diarrhea cases meeting stool-sampling criteria ($P_{SS}$). This factor accounted for patients who visited the study clinics and met the stool specimen collection criteria, but did not provide a specimen, and patients whose specimens were excluded due to technical issues. The formula below shows how we calculated the adjusted incidence at the study clinic:

$$ Study \text{ clinic incidence} = \frac{\text{Crude incidence}}{P_{SS}} $$

The second adjustment factor was the proportion of diarrhea patients who visited the study clinic among diarrhea patients who visited any clinics including non-study clinics ($P_{SC}$). The denominator of this proportion was obtained from the household surveillance, which detected diarrhea patients who visited non-study clinics. The outpatient incidence was calculated as follows:

$$ Outpatient \text{ incidence} = \frac{\text{Crude incidence}}{P_{SS} \times P_{SC}} $$

The third adjustment factor was the proportion of diarrhea patients who visited any clinic among all diarrhea patients identified in the community, including those who did not seek medical care ($P_{MC}$). The household surveillance data enabled us to detect all diarrhea patients in the study sites, and collect information as to whether they accessed any clinic, the determinants of which include a variety of factors. For example, the symptoms were not severe enough to warrant a clinic visit, or simply people made a decision about accessing (or was able to access) a clinic, which may have been unrelated to illness severity. The community incidence was defined as follows:

$$ Community \text{ incidence} = \frac{\text{Crude incidence}}{P_{SS} \times P_{SC} \times P_{MC}} $$

These adjusted incidence rates and their respective 95% credible intervals (CI) were computed using Monte Carlo simulation. We constructed a normal distribution around each of three adjustment factors based on their numerators and denominators, and randomly selected one value from each of the distributions. The crude incidence rates were then divided by these...
selected values. This process was repeated 100,000 times and the median was reported as the point estimate of adjusted incidence and 2.5\textsuperscript{th} and 97.5\textsuperscript{th} percentile as the 95\% CI.

Ethical approvals
Written informed consent was obtained for data collection at the clinics and households. The protocol, surveillance questionnaires and consent forms were reviewed and approved by the Ethical Review Committee at KEMRI (protocol number 932 and 1899) and the Institutional Review Board of CDC-Atlanta (protocol number 4566).

Results
Characteristics of the study population
The patients of this study submitted a total of 336 and 558 stool specimens in Lwak and Kibera, respectively, during the study periods. In Lwak, two stool specimens were excluded from analysis, because these specimens were collected within 14 days since the collection of the initial specimens from the same patients and, thus, considered part of the same episode. In Kibera, a total of 34 stool specimens were excluded from the analysis; 33 were excluded because of missing date of birth, date of specimen collection, or patient ID number, and one was excluded because it was collected within 14 days of another specimen from the same patient. Thus, a total of 334 and 524 stool specimens representing unique episodes of diarrhea were included in the analysis in Lwak and Kibera, respectively. Of these, 18 and 27 patients experienced more than one unique episode of diarrhea during the study periods in Lwak and Kibera, respectively. Both genders were well represented among the study populations in both sites; 155 (46\%) and 257 (49\%) episodes of diarrhea were observed among males in Lwak and Kibera, respectively. The surveillance participants in Lwak were older (median age 27.0 years, range 0–85 years) than Kibera (median age 9.6 years, range 0–67 years). Children <5 years of age represented 19\% of the study population in Lwak and 40\% in Kibera.

Prevalence of enteric pathogens
In both study sites, norovirus was the most common etiology, detected in 85 (25\%) of 334 specimens in Lwak and 159 (30\%) of 524 specimens in Kibera (Table 1). Among norovirus positive specimens, genogroup (G) II predominated in both sites, detected in 74 (87\%) in Lwak and 140 (88\%) in Kibera. Coinfection with GI and GII was found in 6 (7\%) norovirus-positive specimens in Lwak and 14 (9\%) in Kibera. Overall, the prevalence of sapovirus and astrovirus was low (3–8\%) in both study sites. Sapovirus was more prevalent than astrovirus in Kibera, while the opposite was found in Lwak. All viruses were more frequently detected among diarrhea patients aged <5 years compared to those ≥5 years of age in Kibera (p<0.05). The same trend was observed in Lwak, but the difference between the two age groups was not statistically significant.

As shown in Table 2, 311 specimens were positive for at least one of norovirus, sapovirus, or astrovirus. Of these, 28 (9\%) and 82 (26\%) also tested positive for rotavirus and bacteria, respectively. The proportion of rotavirus coinfection was the highest among patients with complicated diarrhea (9/50, 18\%), while coinfection with bacteria occurred most frequently among patients with dysentery (40/84, 48\%). Among the 82 specimens in which coinfections of bacteria and at least one of norovirus, sapovirus, or astrovirus were found, Shigella spp. (n = 65, 79\%) were most frequently identified, followed by Campylobacter spp. (n = 9, 11\%), and Salmonella spp. (n = 7, 9\%). Given the potential for asymptomatic (i.e., non-etiologic) detection of
norovirus, sapovirus, and astrovirus, we excluded stool specimens from the numerator of crude incidence calculation if they were coinfected with rotavirus and/or bacteria.

Clinical profile of norovirus, sapovirus, and astrovirus

The patients with multiple enteric viruses were excluded from the analysis of the clinical profile of norovirus, sapovirus, and astrovirus infections. Uncomplicated diarrhea was most commonly observed among the three types of diarrhea used as the stool collection criteria, followed by dysentery (Table 3). The majority of patients had 3–10 loose stools per day for 1–4 days, regardless of etiology. Vomiting and fever (temperature greater than 37.0°C) were observed in less than half of the patients. No significant difference in clinical profile was observed among the three different viral etiologies.

Crude and adjusted incidence of diarrheal illness

The overall crude incidence rates of norovirus, sapovirus, and astrovirus-associated diarrheal illnesses were 187, 28, and 59 per 100,000 PYO in Lwak (Table 4) and 184, 39, and 20 per 100,000 PYO in Kibera (Table 5). The crude incidence rates of all viruses were the highest among children <12 months of age in both sites. As shown in Fig 2, there was no clear seasonality of crude incidence rates of diarrheal illness associated with these enteric viruses. The annualized crude incidence of norovirus and astrovirus exhibited a large peak in November.
and April, respectively, in Lwak, but a similar trend by month was not observed in Kibera. The annualized crude incidence of sapovirus was low throughout the year in both sites. The proportion of diarrhea patients with a stool specimen (PSS) was low in both sites (14% in Lwak and 12% in Kibera), and appeared to be even lower among younger children (Tables 4 and 5). About half (53%) of the patients who sought medical attention in Lwak and 80% of them in Kibera presented at the study clinics (PSC). After adjusting the crude incidence rates by PSS and PSC, the overall outpatient incidence rates of norovirus, sapovirus, and astrovirus-associated diarrheal illnesses became 2,619, 393, and 829 per 100,000 PYO in Lwak and 1,937, 414, and 207 per 100,000 PYO in Kibera. In both sites, norovirus was the most prevalent among all age groups. The highest outpatient incidence rates for all viruses detected were observed among children <12 months of age (Fig 3A). The outpatient incidence associated with detection of norovirus decreased by 17% in Lwak and 62% in Kibera in children 12–23 months of age compared to children <12 months of age.

Table 2. Detection of enteric pathogens stratified by stool specimen collection criteria, Kenya.

|                        | Uncomplicated diarrhea<sup>a</sup> (n = 483) | Complicated diarrhea<sup>b</sup> (n = 101) | Dysentery<sup>c</sup> (n = 274) |
|------------------------|--------------------------------------------|-------------------------------------------|---------------------------------|
| **Single infection, no. (%)** |                                           |                                           |                                 |
| NoV                    | 102 (21)                                   | 23 (23)                                   | 31 (11)                         |
| SaV                    | 9 (2)                                      | 4 (4)                                     | 7 (3)                           |
| HAstV                  | 12 (2)                                     | 6 (6)                                     | 4 (1)                           |
| RV                     | 20 (4)                                     | 4 (4)                                     | 5 (2)                           |
| Bacteria               | 71 (15)                                    | 11 (11)                                   | 76 (28)                         |
| **Coinfection, no. (%)** |                                           |                                           |                                 |
| NoV + RV               | 6 (1)                                      | 5 (5)                                     | 1 (0)                           |
| NoV + Bacteria         | 25 (5)                                     | 2 (2)                                     | 24 (9)                          |
| NoV + RV + Bacteria    | 3 (1)                                      | 2 (2)                                     | 4 (1)                           |
| NoV + SaV              | 4 (1)                                      | 0 (0)                                     | 0 (0)                           |
| NoV + SaV + RV         | 0 (0)                                      | 1 (1)                                     | 0 (0)                           |
| NoV + SaV + Bacteria   | 1 (0)                                      | 1 (1)                                     | 0 (0)                           |
| NoV + HAstV + Bacteria | 0 (0)                                      | 1 (1)                                     | 0 (0)                           |
| NoV + HAstV + RV       | 0 (0)                                      | 1 (1)                                     | 0 (0)                           |
| NoV + HAstV + Bacteria | 2 (0)                                      | 1 (1)                                     | 0 (0)                           |
| SaV + HAstV            | 1 (0)                                      | 0 (0)                                     | 1 (0)                           |
| SaV + RV               | 3 (1)                                      | 2 (2)                                     | 0 (0)                           |
| SaV + Bacteria         | 2 (0)                                      | 0 (0)                                     | 0 (0)                           |
| SaV + HAstV + RV       | 2 (0)                                      | 0 (0)                                     | 5 (2)                           |
| SaV + HAstV + Bacteria | 1 (0)                                      | 0 (0)                                     | 0 (0)                           |
| HAstV + Bacteria       | 4 (1)                                      | 1 (1)                                     | 5 (2)                           |
| RV + Bacteria          | 6 (1)                                      | 3 (3)                                     | 9 (3)                           |
| **No pathogens detected, no. (%)** |                                           |                                           |                                 |
|                        | 209 (43)                                   | 33 (33)                                   | 100 (36)                        |

NoV: norovirus; SaV: sapovirus; HAstV: astrovirus; RV: rotavirus.

There were 19 specimens that lacked bacteria and/or rotavirus testing, and they are included in the table as bacteria negative and/or rotavirus negative. Data from two study sites are combined in this table.

<sup>a</sup> Uncomplicated diarrhea is defined as three or more loose stools within a 24-hour period, without signs or symptoms of dehydration or dysentery.

<sup>b</sup> Complicated diarrhea is diarrhea with dehydration, which was defined as drinking eagerly, being unable to drink or breastfeed, emesis, slow capillary refill (two seconds or more), irritability, sunken eyes, lethargy or unconsciousness.

<sup>c</sup> Dysentery is defined as reported or visible blood in one or more stool within 24 hours of clinic visit.

doi:10.1371/journal.pone.0145943.t002
The overall healthcare seeking rate for acute diarrheal illness ($P_{MC}$) was lower in Lwak (27%) versus Kibera (47%) and decreased as age increased in both sites (Tables 4 and 5). By adjusting the outpatient incidence rates by $P_{MC}$, the overall community incidence rates per 100,000 PYO of all viruses were found to be higher in Lwak (norovirus: 9,635; sapovirus: 1,445; astrovirus: 3,051) than in Kibera (norovirus: 4,116; sapovirus: 879; astrovirus: 440). Overall, the community incidence rates of all viruses were the highest among children aged <24 months and decreased as age increased (Fig 3B). In Kibera, the community incidence of all viruses were low among people aged ≥5 years, but an increase in norovirus was observed among people aged ≥50 years.

**Discussion**

To our knowledge, this is the first study to estimate the outpatient and community incidence rates of norovirus, sapovirus, and astrovirus-associated diarrheal illnesses across the whole age
| Age group | NoV | SaV | HAsTV |
|-----------|-----|-----|--------|
| <12 months | NoV | 5 | 0 | 3 |
| | PYO | 1049 | 1049 | 1049 |
| | % cases with stool specimen (PSS) | 477 | 191 | 286 |
| | Crude incidence | 6.2 | 6.2 | 6.2 |
| | Study clinic incidence per 100,000 PYO | 7700 | 3080 | 4620 |
| | % cases visiting study clinics (PSC) | 54.3 | 54.3 | 54.3 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 14178 (10507 to 21589) | 5671 (4203 to 8635) | 8507 (6304 to 12953) |
| | % cases visiting any clinic (PMC) | 40.7 | 40.7 | 40.7 |
| | Community incidence per 100,000 PYO (95% CI) | 34900 (25669 to 53294) | 13960 (10268 to 21318) | 20940 (15402 to 31976) |

| 12–23 months | NoV | 4 | 2 | 1 |
| | PYO | 953 | 953 | 953 |
| | % cases with stool specimen (PSS) | 420 | 210 | 35 |
| | Crude incidence | 7.0 | 7.0 | 5.8 |
| | Study clinic incidence per 100,000 PYO | 5955 | 2978 | 607 |
| | % cases visiting study clinics (PSC) | 50.8 | 50.8 | 50.8 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 11736 (8486 to 18663) | 5868 (4243 to 9331) | 17654 (12738 to 28138) |
| | % cases visiting any clinic (PMC) | 33.2 | 33.2 | 33.2 |
| | Community incidence per 100,000 PYO (95% CI) | 35308 (25477 to 56276) | 17654 (12738 to 28138) |

| 24–59 months | NoV | 3 | 1 | 1 |
| | PYO | 2836 | 2836 | 2836 |
| | % cases with stool specimen (PSS) | 106 | 35 | 35 |
| | Crude incidence | 5.8 | 5.8 | 5.8 |
| | Study clinic incidence per 100,000 PYO | 1822 | 607 | 607 |
| | % cases visiting study clinics (PSC) | 53.1 | 53.1 | 53.1 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 3438 (2412 to 5892) | 1146 (804 to 1964) | 1146 (804 to 1964) |
| | % cases visiting any clinic (PMC) | 27.7 | 27.7 | 27.7 |
| | Community incidence per 100,000 PYO (95% CI) | 12423 (8669 to 21370) | 4141 (2890 to 7123) | 4141 (2890 to 7123) |

| 5–9 years | NoV | 5 | 1 | 1 |
| | PYO | 5357 | 5357 | 5357 |
| | % cases with stool specimen (PSS) | 93 | 35 | 35 |
| | Crude incidence | 11.6 | 5.8 | 5.8 |
| | Study clinic incidence per 100,000 PYO | 804 | 607 | 607 |
| | % cases visiting study clinics (PSC) | 50.5 | 50.5 | 50.5 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 1596 (1131 to 2621) | 1146 (804 to 1964) | 1146 (804 to 1964) |
| | % cases visiting any clinic (PMC) | 24.4 | 24.4 | 24.4 |
| | Community incidence per 100,000 PYO (95% CI) | 6554 (4591 to 10860) | 4141 (2890 to 7123) | 4141 (2890 to 7123) |

| 10–17 years | NoV | 8 | 1 | 1 |
| | PYO | 6662 | 6662 | 6662 |
| | % cases with stool specimen (PSS) | 120 | 15 | 15 |
| | Crude incidence | 13.5 | 13.5 | 13.5 |
| | Study clinic incidence per 100,000 PYO | 887 | 111 | 111 |
| | % cases visiting study clinics (PSC) | 53.3 | 53.3 | 53.3 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 1666 (1281 to 2341) | 208 (160 to 293) | 208 (160 to 293) |
| | % cases visiting any clinic (PMC) | 23.9 | 23.9 | 23.9 |
| | Community incidence per 100,000 PYO (95% CI) | 6992 (5287 to 9824) | 874 (661 to 1241) | 874 (661 to 1241) |

| 18–34 years | NoV | 16 | 4 | 4 |
| | PYO | 7229 | 7229 | 7229 |
| | % cases with stool specimen (PSS) | 221 | 55 | 55 |
| | Crude incidence | 24.8 | 24.8 | 24.8 |
| | Study clinic incidence per 100,000 PYO | 892 | 223 | 223 |
| | % cases visiting study clinics (PSC) | 53.1 | 53.1 | 53.1 |
| | Outpatient incidence per 100,000 PYO (95% CI) | 1682 (1419 to 2053) | 421 (355 to 513) | 421 (355 to 513) |
| | % cases visiting any clinic (PMC) | 28.9 | 28.9 | 28.9 |
| | Community incidence per 100,000 PYO (95% CI) | 5832 (4838 to 7186) | 1458 (1210 to 1792) | 1458 (1210 to 1792) |
| AGE group | NoV | SaV | HAsIV |
|-----------------|------|-----|-------|
| 35–49 years | 11 | 3347 | 329 | 23.5 | 1400 | 53.5 | 2622 | (2102 to 3423) |
| | SaV | 1 | 3347 | 30 | 23.5 | 127 | 53.5 | 238 | (191 to 311) |
| | HAsIV | 3 | 3347 | 90 | 23.5 | 382 | 53.5 | 715 | (573 to 933) |
| ≥50 years | 8 | 4636 | 173 | 21.7 | 793 | 52.2 | 1523 | (1227 to 1981) |
| | SaV | 0 | 4636 | 0 | 21.7 | 0 | 52.2 | 0 | 17.6 | 9963 (717 to 1197) |
| | HAsIV | 1 | 4636 | 22 | 21.7 | 99 | 52.2 | 190 | (153 to 248) |
| <5 years | 12 | 4838 | 248 | 6.3 | 3920 | 52.8 | 7430 | (6094 to 9471) |
| | SaV | 3 | 4838 | 62 | 6.3 | 980 | 52.8 | 1858 | (1524 to 2368) |
| | HAsIV | 6 | 4838 | 124 | 6.3 | 1960 | 52.8 | 3715 | (3047 to 4736) |
| ≥5 years | 48 | 27231 | 176 | 19.7 | 893 | 52.6 | 1697 | (1527 to 1905) |
| | SaV | 6 | 27231 | 22 | 19.7 | 112 | 52.6 | 212 | (191 to 238) |
| | HAsIV | 13 | 27231 | 48 | 19.7 | 242 | 52.6 | 460 | (414 to 516) |
| Sex | NoV | SaV | HAsIV |
| Male | 31 | 15177 | 204 | 12.7 | 1603 | 52.1 | 3073 | (2674 to 3598) |
| | SaV | 4 | 15177 | 26 | 12.7 | 207 | 52.1 | 397 | (345 to 464) |
| | HAsIV | 6 | 15177 | 40 | 12.7 | 310 | 52.1 | 595 | (517 to 696) |
| Female | 29 | 16892 | 172 | 14.3 | 1199 | 53.2 | 2256 | (1988 to 2601) |
| | SaV | 5 | 16892 | 30 | 14.3 | 207 | 53.2 | 389 | (343 to 448) |
| | HAsIV | 13 | 16892 | 77 | 14.3 | 538 | 53.2 | 1011 | (891 to 1166) |

(Continued)
Table 4. (Continued)

| Number of AGE cases positive for each virus | PYO | Crude incidence | Study clinic % cases with stool specimen (Pss) | Study clinic incidence per 100,000 PYO | % cases visiting study clinics (Psc) | Outpatient incidence per 100,000 PYO (95% CI) | % cases visiting any clinic (Pmc) | Community incidence per 100,000 PYO (95% CI) |
|--------------------------------------------|-----|-----------------|---------------------------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|---------------------------------------|---------------------------------------------|
| Total                                      | NoV | 60              | 32069                                       | 187                                    | 13.6                                | 1380                                        | 52.7                                  | 2619                                        |
|                                            |     |                 |                                             |                                        |                                     | (2380 to 2907)                           | 27.2                                  | 9635                                        |
| SaV                                        | 9   | 32069           | 28                                          | 13.6                                   | 207                                 | 52.7                                       | 393                                   | (357 to 436)                              |
|                                            |     |                 |                                             |                                        |                                     | (357 to 436)                              | 27.2                                  | 1445                                        |
| HAstV                                      | 19  | 32069           | 59                                          | 13.6                                   | 437                                 | 52.7                                       | 829                                   | (754 to 920)                              |
|                                            |     |                 |                                             |                                        |                                     | (754 to 920)                              | 27.2                                  | 3051                                        |

NoV: norovirus; SaV: sapovirus; HAstV: astrovirus; PYO: person-years of observation; AGE: acute gastroenteritis; 95% CI: 95% credible interval.

doi:10.1371/journal.pone.0145943.t004
Table 5. Crude and adjusted incidence rates for norovirus, sapovirus, and astrovirus-associated diarrheal illness, Kibera, Kenya.

| Age group          | Number of AGE cases positive for each virus | PYO | Crude incidence | % cases with stool specimen (Pss) | Study clinic incidence per 100,000 PYO | % cases visiting study clinics (Psc) | Outpatient incidence per 100,000 PYO (95% CI) | % cases visiting any clinic (Pmc) | Community incidence per 100,000 PYO (95% CI) |
|--------------------|---------------------------------------------|-----|-----------------|----------------------------------|----------------------------------------|--------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------|
| <12 months         | NoV                                         | 16  | 1543            | 1037                             | 5.2                                    | 19785                                | 76.8 (PSS)                                 | 25768 (20930 to 33448)           | 57.2 (36395 to 58670)                     |
|                    | SaV                                         | 5   | 1543            | 324                              | 5.2                                    | 6183                                 | 76.8 (PSS)                                 | 8053 (6541 to 10453)              | 57.2 (11373 to 18334)                    |
|                    | HaAstV                                      | 5   | 1543            | 324                              | 5.2                                    | 6183                                 | 76.8 (PSS)                                 | 8053 (6541 to 10453)              | 57.2 (11373 to 18334)                    |
| 12–23 months       | NoV                                         | 11  | 2237            | 492                              | 6.1                                    | 8057                                 | 82.9 (PSS)                                 | 9718 (8317 to 11650)              | 50.0 (16577 to 23420)                    |
|                    | SaV                                         | 3   | 2237            | 134                              | 6.1                                    | 2197                                 | 82.9 (PSS)                                 | 2650 (2268 to 3177)               | 50.0 (4521 to 6387)                     |
|                    | HaAstV                                      | 3   | 2237            | 134                              | 6.1                                    | 2197                                 | 82.9 (PSS)                                 | 2650 (2268 to 3177)               | 50.0 (4521 to 6387)                     |
| 24–59 months       | NoV                                         | 29  | 6406            | 453                              | 10.8                                   | 4180                                 | 83.0 (PSS)                                 | 5037 (4515 to 5687)               | 43.5 (10311 to 13182)                    |
|                    | SaV                                         | 6   | 6406            | 94                               | 10.8                                   | 865                                  | 83.0 (PSS)                                 | 1042 (934 to 1177)                | 43.5 (2133 to 2727)                     |
|                    | HaAstV                                      | 1   | 6406            | 16                               | 10.8                                   | 144                                  | 83.0 (PSS)                                 | 174 (156 to 196)                  | 43.5 (356 to 455)                      |
| 5–9 years          | NoV                                         | 12  | 8485            | 141                              | 17.6                                   | 801                                  | 84.7 (PSS)                                 | 946 (809 to 1136)                | 44.1 (1804 to 2615)                    |
|                    | SaV                                         | 5   | 8485            | 59                               | 17.6                                   | 334                                  | 84.7 (PSS)                                 | 394 (337 to 473)                 | 44.1 (752 to 1090)                     |
|                    | HaAstV                                      | 1   | 8485            | 12                               | 17.6                                   | 67                                   | 84.7 (PSS)                                 | 79 (67 to 95)                    | 44.1 (150 to 218)                      |
| 10–17 years        | NoV                                         | 8   | 8582            | 93                               | 22.8                                   | 410                                  | 84.7 (PSS)                                 | 484 (400 to 609)                 | 41.0 (946 to 1533)                     |
|                    | SaV                                         | 0   | 8582            | 0                                | 22.8                                   | 0                                    | 84.7 (PSS)                                 | 0 (0 to 0)                       | 41.0 (0 to 0)                          |
|                    | HaAstV                                      | 0   | 8582            | 0                                | 22.8                                   | 0                                    | 84.7 (PSS)                                 | 0 (0 to 0)                       | 41.0 (0 to 0)                          |
| 18–34 years        | NoV                                         | 19  | 20698           | 92                               | 20.5                                   | 447                                  | 73.0 (PSS)                                 | 612 (541 to 704)                | 42.3 (1254 to 1693)                    |
|                    | SaV                                         | 2   | 20698           | 10                               | 20.5                                   | 47                                   | 73.0 (PSS)                                 | 64 (57 to 74)                    | 42.3 (132 to 178)                      |
|                    | HaAstV                                      | 1   | 20698           | 5                                | 20.5                                   | 24                                   | 73.0 (PSS)                                 | 32 (28 to 37)                    | 42.3 (66 to 89)                        |

(Continued)
Table 5. (Continued)

| Age Group | Virus | Number of AGE cases positive for each virus | PYO | Crude incidence | % cases with stool specimen (P_{SS}) | Study clinic incidence per 100,000 PYO | Outpatient incidence per 100,000 PYO (95% CI) | % cases visiting study clinics per 100,000 PYO (P_{SC}) | Community incidence per 100,000 PYO (95% CI) |
|-----------|-------|---------------------------------------------|-----|----------------|-------------------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 35–49 years | NoV | 5 | 6660 | 75 | 25.5 | 294 | 67.8 | 435 | (366 to 527) | 39.9 | 1092 | (893 to 1361) |
| SaV | 1 | 6660 | 15 | 25.5 | 59 | 67.8 | 87 | (73 to 105) | 39.9 | 218 | (179 to 272) |
| HAstV | 0 | 6660 | 0 | 25.5 | 0 | 67.8 | 0 | (0 to 0) | 39.9 | 0 | (0 to 0) |
| ≥50 years | NoV | 3 | 1458 | 206 | 18.5 | 1112 | 79.0 | 1416 | (998 to 2310) | 42.5 | 3347 | (2247 to 5630) |
| SaV | 0 | 1458 | 0 | 18.5 | 0 | 79.0 | 0 | (0 to 0) | 42.5 | 0 | (0 to 0) |
| HAstV | 0 | 1458 | 0 | 18.5 | 0 | 79.0 | 0 | (0 to 0) | 42.5 | 0 | (0 to 0) |
| <5 years | NoV | 56 | 10187 | 550 | 7.9 | 6981 | 81.1 | 8604 | (7908 to 9427) | 49.1 | 17511 | (16042 to 19250) |
| SaV | 14 | 10187 | 137 | 7.9 | 1745 | 81.1 | 2151 | (1977 to 2357) | 49.1 | 4378 | (4011 to 4812) |
| HAstV | 9 | 10187 | 88 | 7.9 | 1122 | 81.1 | 1383 | (1271 to 1515) | 49.1 | 2814 | (2578 to 3094) |
| ≥5 years | NoV | 47 | 45883 | 102 | 20.9 | 491 | 77.3 | 636 | (598 to 690) | 42.2 | 1506 | (1379 to 1651) |
| SaV | 8 | 45883 | 17 | 20.9 | 84 | 77.3 | 108 | (100 to 117) | 42.2 | 256 | (235 to 281) |
| HAstV | 2 | 45883 | 4 | 20.9 | 21 | 77.3 | 27 | (25 to 29) | 42.2 | 64 | (59 to 70) |

**Sex**

| Gender | Virus | Number of AGE cases positive for each virus | PYO | Crude incidence | % cases with stool specimen (P_{SS}) | Study clinic incidence per 100,000 PYO | Outpatient incidence per 100,000 PYO (95% CI) | % cases visiting study clinics per 100,000 PYO (P_{SC}) | Community incidence per 100,000 PYO (95% CI) |
|--------|-------|---------------------------------------------|-----|----------------|-------------------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Male | NoV | 51 | 28442 | 179 | 11.9 | 1508 | 80.0 | 1885 | (1738 to 2056) | 47.4 | 3979 | (3649 to 4360) |
| SaV | 12 | 28442 | 42 | 11.9 | 355 | 80.0 | 443 | (409 to 484) | 47.4 | 936 | (859 to 1026) |
| HAstV | 3 | 28442 | 11 | 11.9 | 89 | 80.0 | 111 | (102 to 121) | 47.4 | 234 | (215 to 256) |
| Female | NoV | 52 | 27629 | 188 | 11.8 | 1598 | 80.3 | 1991 | (1836 to 2172) | 46.7 | 4260 | (3910 to 4669) |
| SaV | 10 | 27629 | 36 | 11.8 | 307 | 80.3 | 383 | (353 to 418) | 46.7 | 819 | (732 to 898) |
| HAstV | 8 | 27629 | 29 | 11.8 | 246 | 80.3 | 306 | (283 to 334) | 46.7 | 655 | (602 to 718) |
| Total | NoV | 103 | 56070 | 184 | 11.8 | 1552 | 80.1 | 1937 | (1828 to 2059) | 47.1 | 4116 | (3871 to 4389) |
| SaV | 22 | 56070 | 39 | 11.8 | 331 | 80.1 | 414 | (390 to 440) | 47.1 | 879 | (827 to 938) |
| HAstV | 11 | 56070 | 20 | 11.8 | 166 | 80.1 | 207 | (195 to 220) | 47.1 | 440 | (413 to 469) |

NoV: norovirus; SaV: sapovirus; HAstV: astrovirus; PYO: person-years of observation; AGE: acute gastroenteritis; 95% CI: 95% credible interval.
spectrum in Africa. Our analysis demonstrated a substantial disease burden imposed by these viruses in both rural and urban Kenya. Norovirus had the highest incidence rates in both sites. In addition, sapovirus and astrovirus, for which epidemiological data remain limited globally, were also found to be of considerable disease burden in Kenya. The combination of household surveillance and clinic surveillance enabled us to identify patients with diarrhea in the study sites comprehensively, and provided robust estimates of incidence at the outpatient and community levels by adjusting for the proportion of patients that were missed at the study clinics. These adjustments revealed the total community burden of disease associated with each virus, which could not have been observed from the crude incidence rates alone. For example, the overall crude incidence of norovirus was about same in Kibera than in Lwak, but the overall outpatient and community incidence rates were calculated to be about 1.4 and 2.3-fold higher in Lwak than in Kibera, respectively. These findings demonstrated the importance of assessing healthcare seeking behaviors and access to care issues in the context of surveillance studies for disease burden estimates. We did not detect an apparent or consistent trend in seasonality at either study site. Both study sites have two rainy seasons (from March to May and from October to November) [15], but no viruses at either of the sites peaked during both rainy seasons.

According to the 2009 census, there were 26.1 million and 12.5 million people of all ages living in rural and urban Kenya, respectively [23]. By applying the adjusted incidence rates in Lwak to the population in rural Kenya and those in Kibera to the population in urban Kenya,
Fig 3. Adjusted outpatient (A) and community (B) incidence rates of enteric viruses per 100,000 PYO by age group, Lwak and Kibera, Kenya. NoV: norovirus, SaV: sapovirus, HAstV: astrovirus; PYO: person-years of observation. The outpatient incidence was calculated by dividing the crude incidence by the proportion of patients who submitted stool specimen among all diarrhea patients meeting stool-sampling criteria (PSS) and the proportion of diarrhea patients who visited the study clinic among diarrhea patients who visited any clinics including non-study clinics (PSC). The community incidence was calculated by dividing the outpatient incidence by the proportion of diarrhea patients who visited any clinics among all diarrhea patients identified in the community, including those who did not seek medical care (PMC).

doi:10.1371/journal.pone.0145943.g003
we estimate that each year, about 2.8–3.3 million, 0.45–0.54 million, and 0.77–0.95 million people across all ages in Kenya become ill with diarrheal illness in the presence of norovirus, sapovirus, and astrovirus, respectively. Of these, approximately 0.85–1.0 million, 0.14–0.17 million, and 0.22–0.27 million people of all ages with norovirus, sapovirus, and astrovirus-associated diarrheal illnesses seek outpatient care each year in Kenya, respectively. These extrapolations are based on the assumption that the incidence estimated in the single rural and urban study sites reflect the incidence in all rural and urban areas of Kenya, respectively. This assumption may not be appropriate especially for urban areas where the population size is not stable because of frequent movement in and out of the area. Due to this assumption and other limitations discussed later, these extrapolations may not yield precise national estimates. Nonetheless, the magnitude of these estimates suggests the significant burden of these enteric viruses on the people and healthcare system in Kenya and the importance of targeted public health interventions for these enteric viruses. Compared to the outpatient incidence of rotavirus estimated in the same sites among children aged <5 years from 2007 to 2010 (before introduction of rotavirus vaccine into the national immunization program in 2014) [14], the outpatient incidence of norovirus was estimated to be 10% higher in Lwak and 46% higher in Kibera among the same age group. Among the total population across all age groups, the outpatient incidence of norovirus was about 2-fold higher than that of rotavirus in both sites. Although rotavirus was detected by enzyme immunoassay in the previous study, which is less sensitive than RT-PCR, these findings suggest that norovirus is comparably or even more prevalent than rotavirus among diarrhea patients in the outpatient setting. As diarrheal disease caused by rotavirus decreases with the introduction of rotavirus vaccines [24, 25], the relative burden of norovirus is expected to increase in the future.

Comparison of our study findings with similar studies conducted in developed countries reveals consistent trends and key differences. For example, the estimated community incidence rates of norovirus disease per 100,000 population across all age groups was 6,500–7,000 in the U.S. [26–28], 3,800 in the Netherlands [29], and 4,500–4,700 in the United Kingdom [30, 31]. Although these estimates were computed by various methods, rates of norovirus-associated diseases appear to be 1.2–2.1-fold higher in Kenya compared to those in developed countries. With regard to adjustment factors for healthcare utilization, the rate of stool specimen submission was low (5–11%) among younger children and was the highest (21–26%) among patients aged 18–49 years in both sites in Kenya (Table 3). This is contrary to a previous study’s observation in the U.S., where young children and the elderly were more likely to submit stool specimens and only less than 1% of patients aged 16–25 years provided specimens [28]. This observation highlights the importance of obtaining the site specific adjustment factors in order to estimate an outpatient and community incidence of diseases.

An important limitation of this study is the lack of non-diarrheal or healthy control specimens. As such, we were not able to adjust the attributable fraction to account for asymptomatic viral detection, as has been done previously [14]. However, we conservatively limited our incidence estimates for norovirus, sapovirus, and astrovirus to only include diarrhea patients that were not positive for another known pathogen (i.e., enteric bacteria or rotavirus), providing some reassurance that these were etiologic detections. Other studies have detected these viruses more frequently in specimens collected from cases compared to those from controls, suggesting that these three viruses are indeed etiologic causes of diarrheal illnesses [32–34]. It should be also noted that specimens were not tested for other causes of diarrhea, such as parasites and adenovirus. Although norovirus was detected as a single pathogen in 11% of dysentery cases, these cases may have been caused by other pathogens that were not tested in our study or may represent false negatives of the bacteria testing. There is also a potential that the clinic surveillance missed patients with mild diarrhea, because we did not collect stool specimens from all
patients who experienced uncomplicated diarrhea. As norovirus is known to more often cause less severe diarrhea, some cases with norovirus-associated uncomplicated diarrhea were likely missed at the study clinics, possibly causing an underestimation of our incidence rates. Another potential limitation is selection bias among patients that submitted stool specimens and sought medical care at the study clinics, which would limit the representativeness of the data on viral detection from stools. In addition, because our study periods were not a set on full calendar years, there is potential for seasonal bias; however, our study was performed for at least one full calendar year in both sites and our analysis showed there was no clear seasonality in either site.

In conclusion, our study is the first to provide population-based incidence estimates of diarrheal illness associated with norovirus, sapovirus, and astrovirus across the age spectrum in Kenya, and one of the few studies providing such estimates worldwide. The substantial disease burden of norovirus, which is comparable to that of rotavirus, underscores the potential value of targeted interventions, such as vaccines, to reduce the health burden of norovirus. Data from our study can inform cost-effectiveness of potential vaccines against norovirus and help define a public health strategy for controlling these enteric viruses in developing countries.

Acknowledgments

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Author Contributions

Conceived and designed the experiments: JV UDP JMM DRF RFB AJH. Performed the experiments: LC AA NG. Analyzed the data: KS LC AA AJH. Contributed reagents/materials/analysis tools: KS LC AA NG AJH. Wrote the paper: KS.

References

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014. Epub 2014/12/23. doi:10.1016/s0140-6736 (14)61682-2 PMID: 25530442.

2. Fischer Walker CL, Perin J, Aryee MJ, Boschi-Pinto C, Black RE. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. BMC Public Health. 2012; 12:220. Epub 2012/03/23. doi:10.1186/1471-2458-12-220 PMID: 22436130; PubMed Central PMCID: PMC333412.

3. Tsolenyanu E, Seheri M, Dagnra A, Djadou E, Tigossou S, Nyaga M, et al. Surveillance for rotavirus gastroenteritis in children less than 5 years of age in Togo. Pediatr Infect Dis J. 2014; 33 Suppl 1:S14–8. Epub 2013/12/18. doi: 10.1097/inf.0000000000000046 PMID: 2434607.

4. Abebe A, Teka T, Kassa T, Seheri M, Beyene B, Teshome B, et al. Hospital-based surveillance for rotavirus gastroenteritis in children younger than 5 years of age in Ethiopia: 2007–2012. Pediatr Infect Dis J. 2014; 33 Suppl 1:S28–33. Epub 2013/12/18. doi: 10.1097/inf.0000000000000048 PMID: 24343610.

5. Khagayi S, Burton DC, Onkoba R, Ochieng B, Ismail A, Mutonga D, et al. High burden of rotavirus gastroenteritis in young children in rural western Kenya, 2010–2011. Pediatr Infect Dis J. 2014; 33 Suppl 1:S34–40. Epub 2013/12/18. doi: 10.1097/inf.0000000000000049 PMID: 24343611.

6. Mwenda JM, Tate JE, Parashar UD, Mihigo R, Agocs M, Serhan F, et al. African rotavirus surveillance network: a brief overview. Pediatr Infect Dis J. 2014; 33 Suppl 1:S56–8. Epub 2013/12/18. doi: 10.1097/inf.0000000000000174 PMID: 24343616.

7. Ogilvie I, Khoury H, Goetghebeur MM, El Khoury AC, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012; 12:62. Epub 2012/03/21. doi: 10.1186/1471-2253-12-62 PMID: 22429601; PubMed Central PMCID: PMC3342230.

8. Gastanaduy PA, Hall AJ, Curns AT, Parashar UD, Lopman BA. Burden of norovirus gastroenteritis in the ambulatory setting—United States, 2001–2009. J Infect Dis. 2013; 207(7):1058–65. Epub 2013/01/10. doi: 10.1093/infdis/jia942 PMID: 23300161.
9. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014; 14(8):725–30. Epub 2014/07/02. doi: 10.1016/s1473-3099(14)70767-4 PMID: 24981041.

10. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376(9741):606–14. Epub 2010/08/10. doi: 10.1016/s0140-6736(10)60889-6 PMID: 20692030.

11. Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis. 2014; 14(11):1096–104. Epub 2014/10/12. doi: 10.1016/s1473-3099(14)70940-5 PMID: 25303843.

12. Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssemipija V, Audi A, et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine. 2012; 30 Suppl 1:A52–60. Epub 2012/05/02. doi: 10.1016/j.vaccine.2011.08.043 PMID: 22520137.

13. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362(4):289–98. Epub 2010/01/29. doi: 10.1056/NEJMoa0904797 PMID: 20107214.

14. Breiman RF, Cosmas L, Audi A, Mwiti W, Njuguna H, Bigogo GM, et al. Use of population-based surveillance to determine the incidence of rotavirus gastroenteritis in an urban slum and a rural setting in Kenya. Pediatr Infect Dis J. 2014; 33 Suppl 1:S54–61. Epub 2013/12/18. doi: 10.1097/inf.0000000000000994 PMID: 24343615.

15. Feikin DR, Olack B, Bigogo GM, Audi A, Cosmas L, Aura B, et al. The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya. PLoS ONE. 2011; 6(1):e16085. Epub 2011/01/27. doi: 10.1371/journal.pone.0016085 PMID: 21267459; PubMed Central PMCID: PMCPMC3022725.

16. Podkolzin AT, Fenske EB, Abramycheva NY, Shipulin GA, Sagalova OI, Mazepa VN, et al. Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005–2007. J Infect Dis. 2009; 200 Suppl 1:S228–33. Epub 2009/10/13. doi: 10.1086/605054 PMID: 19817602.

17. Hill VR, Mull B, Jothishumar N, Ferdinand K, Vinjé J. Detection of GI and GII Noroviruses in Ground Water Using Ultrafiltration and TaqMan Real-time RT-PCR. Food and Environmental Virolology. 2010; 2(4):218–24.

18. Trujillo JA, McCaustland KA, Zheng DP, Hadley LA, Vaughan G, Adams SM, et al. Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol. 2006; 44(4):1405–12. Epub 2006/04/07. doi: 10.1128/jcm.44.4.1405–1412.2006 PMID: 16597869; PubMed Central PMCID: PMCPMC448641.

19. Kageyama T, Kojima S, Shinohara M, Uchida K, Fukushima S, Hoshino FB, et al. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J Clin Microbiol. 2003; 41(4):1548–57. Epub 2003/04/19. PMID: 12682144; PubMed Central PMCID: PMCPMC153860.

20. Oka T, Katayama K, Hansman GS, Kageyama T, Ogawa S, Wu FT, et al. Detection of human sapovirus by real-time reverse transcription-polymerase chain reaction. J Med Virol. 2006; 78(10):1347–53. Epub 2006/08/24. doi: 10.1002/jmv.20699 PMID: 16927293.

21. Dennehy PH, Gauntlett DR, Spangenberg SE. Choice of reference assay for the detection of rotavirus in fecal specimens: electron microscopy versus enzyme immunoassay. J Clin Microbiol. 1990; 28(6):1280–3. Epub 1990/06/01. PMID: 2166080; PubMed Central PMCID: PMCPmc267919.

22. Krieg N, Holt J, Bergey (1984). Bergey's manual of systematic bacteriology/Krieg Noel R., editor, volume 1; Holt John G., editor-in-chief. Baltimore: Williams & Wilkins 4 v.xxvii, 2648.

23. Kenya National Bureau of Statistics. The 2009 Kenya Population and Housing Census. 2010.

24. Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368(12):1121–30. Epub 2013/03/22. doi: 10.1056/NEJMsa1206589 PMID: 23514289.

25. Hemming M, Rasanen S, Huhtl L, Paloniemi M, Salminen M, Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr. 2013; 172(6):739–46. Epub 2013/01/31. doi: 10.1007/s00431-013-1945-3 PMID: 23361964.

26. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, et al. Norovirus disease in the United States. Emerg Infect Dis. 2013; 19(8):1198–205. Epub 2013/07/24. doi: 10.3201/eid1908.130465 PMID: 23876403; PubMed Central PMCID: PMCPMC3739528.
27. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011; 17(1):7–15. Epub 2011/01/05. doi: 10.3201/eid1701.091101p1 PMID: 21192848; PubMed Central PMCID: PMCPMC3375761.

28. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Hanco MA, et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerg Infect Dis. 2011; 17(8):1381–8. Epub 2011/08/02. doi: 10.3201/eid1708.101533 PMID: 21801613; PubMed Central PMCID: PMCPMC3381564.

29. Verhoef L, Koopmans M, Vanden B, Duizer E, Haagsma J, Werber D, et al. The estimated disease burden of norovirus in The Netherlands. Epidemiol Infect. 2013; 141(3):496–506. Epub 2012/05/19. doi: 10.1017/s0950268812000799 PMID: 22595489.

30. Phillips G, Tam CC, Conti S, Rodrigues LC, Brown D, Iturriza-Gomara M, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol. 2010; 171(9):1014–22. Epub 2010/04/03. doi: 10.1093/aje/kwq021 PMID: 20360244.

31. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut. 2012; 61(1):69–77. Epub 2011/06/29. doi: 10.1136/gut.2011.238386 PMID: 21708822; PubMed Central PMCID: PMCPMC3230829.

32. Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, et al. Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008–2009. J Infect Dis. 2013; 208(5):790–800. Epub 2013/06/13. doi: 10.1093/infdis/jit254 PMID: 23757337.

33. Becker-Dreps S, Bucardo F, Vilchez S, Zambrana LE, Liu L, Weber DJ, et al. Etiology of childhood diarrhea after rotavirus vaccine introduction: a prospective, population-based study in Nicaragua. Pediatr Infect Dis J. 2014; 33(11):1156–63. Epub 2014/06/01. doi: 10.1097/inf.0000000000000427 PMID: 24879131; PubMed Central PMCID: PMCPMC4216626.

34. Donnelly PH, Nelson SM, Spangenberger S, Noel JS, Monroe SS, Glass RI. A prospective case-control study of the role of astrovirus in acute diarrhea among hospitalized young children. J Infect Dis. 2001; 184(1):10–5. Epub 2001/06/09. doi: 10.1086/321007 PMID: 11398103.